FindTrial
Sign In

NKTR-102

DRUG5 trials

Sponsors

Nektar Therapeutics

Conditions

Advanced CancerBreast CancerColorectal CancerLocally Recurrent Breast CancerMetastasisMetastatic Breast CancerMetastatic Solid TumorsTumor

Phase 1

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
CompletedNCT01976143
Nektar TherapeuticsAdvanced Cancer, Metastatic Solid Tumors
Start: 2014-02-28End: 2016-09-30Updated: 2016-12-22

Phase 2

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
CompletedNCT00802945
Nektar TherapeuticsTumor, Breast Cancer
Start: 2008-10-31End: 2012-01-31Updated: 2018-07-09
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
CompletedNCT00856375
Nektar TherapeuticsColorectal Cancer
Start: 2008-12-31End: 2014-12-31Updated: 2021-07-12

Phase 3

The BEACON Study (Breast Cancer Outcomes With NKTR-102)
CompletedNCT01492101
Nektar TherapeuticsLocally Recurrent Breast Cancer, Metastatic Breast Cancer
Start: 2011-12-31End: 2016-06-30Updated: 2021-06-01
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
CompletedNCT02915744
Nektar TherapeuticsMetastasis, Breast Cancer
Start: 2016-11-30End: 2020-07-31Updated: 2023-04-14

Related Papers

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
JAMA Oncology2022-05-1220 citations
ATTAIN: Phase III Study of Etirinotecan Pegol Versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer and Brain Metastases
Future Oncology2019-05-1021 citations
ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
Annals of Oncology2018-10-011 citations
ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).
Journal of Clinical Oncology2018-05-20
Abstract OT2-07-10: ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
Cancer Research2018-02-15
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
2017-06-1332 citations
ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).
Journal of Clinical Oncology2017-05-20
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
2017-03-2712 citations
Abstract P4-11-08: Impact of treatment on quality of life (QOL) in the BEACON study, a randomized phase III trial of etirinotecan pegol (EP) versus treatment of physician's choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C)
Cancer Research2016-02-151 citations
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
2015-10-2256 citations
Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.
Journal of Clinical Oncology2015-05-207 citations